Team:Wageningen UR/Summary

From 2013.igem.org

Revision as of 00:02, 5 October 2013 by Jingjing4028 (Talk | contribs)

Summary

We made mistakes,
though this whole endeavor was incredibly worthwhile.

We learned a lot,
and nothing beats the excitement of positive results.

Concluding our iGEM project in 2013, we introduced Aspergillus niger as a potential host into iGEM. It is an industrially relevant organism, deserving a place in iGEM as a standard synthetic biological chassis. With the host engineering, we stepped further to the next level of synthetic biology.

In this GRAS organism, we established a modular system of domain shuffling in order to express a variety of secondary metabolites. We focused on the production of a medically relevant compound, lovastatin, which has never been produced in A. niger. By synthesizing a range of modules for the main multi-domain enzyme in the lovastatin pathway, a new frame shiftless assembly protocol was developed to design the complexes, and bricked these parts for future teams. Furthermore, the metabolic models we developed to pre-emptively assess the production conditions, and potentially the optimization of production, has hinted at future improvements for A. niger lovastatin production and comply with the need of industry.

Additionally, to target the production of specific compartment, a toolkit including a promoter, terminator, biosensors for pH, ATP, and chromogenic biomarkers, as well as a marker for the cytoskeleton was created successfully. It paved the way for future teams to further exploit this beautiful bug.

Finally, we modified the host by directed evolution. Filamentous fungi are pretty organisms, but multicellularity is not always wanted in fermentations. We set out to solve this defect by evolving mutants with a reduced mycelial cohesiveness. Microscopic analyses have shown that Aspergillus is conditionally dimorphic, and both viable and metabolically active in a single cell morphotype. We made important steps in unraveling the causes of multicellularity.